Investment
Features
FeesSafety
Academy
More
Pluang+

Compare 10X Genomics Inc (TXG) vs Uber Technologies Inc (UBER) Price & Performance

10X Genomics IncTrade
Uber Technologies IncTrade

Price performance (Past 24H)

Key statistics

10X Genomics Inc vs Uber Technologies Inc — how do they compare? 10X Genomics Inc trades at $58.54 (market cap $7.64B), while Uber Technologies Inc trades at $78.35 (market cap $159.38B). The key difference: Uber Technologies Inc is far larger — about 20.9× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals.

TXGUBER
Market Cap
$7.64B$159.38B
Sector
HealthIndustrials
52-Week High
$58.57$100.10
52-Week Low
$11.34$65.94
Enterprise Value
$7.17B$168.72B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

10X Genomics Inc

TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.

The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.

Uber Technologies Inc

Uber (UBER) trades at $78.54, up 4.69% today, reflecting strong bullish momentum. The stock shows robust fundamentals with revenue growth from $44.0B in 2024 to $52.0B in 2025 and a net income margin of 19.32%. Technical indicators are bullish, with the price above key support levels and moving averages signaling upward trend. Recent news highlights strategic moves into autonomous vehicles, including robotaxi pilots in Spain and Germany, though cost management is evident through HR layoffs and AI spending caps.

The outlook for Uber is positive, driven by revenue expansion and profitability improvements, but risks include intense competition and regulatory scrutiny. Analyst consensus is strongly bullish with a $102.88 price target, suggesting significant upside potential from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG

About Uber Technologies Inc

Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.

Read more on UBER